Astrazeneca: Pharma giant snaps up rare disease biotech firm Amoylt

The acquisition, which is meant to "bolster" Astrazenca's rare disease arm Alexion, brings with it a Phase III investigational therapeutic peptide meant for hypoparathyroidism